Korean J Gastrointest Endosc.  2009 Jan;38(1):47-51.

Anti-Tuberculosis Agents Induced Pseudomembranous Colitis Treated with Maintaining Anti-Tuberculosis Drugs

Affiliations
  • 1Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Kwandong University, Goyang, Korea. chg21@kd.ac.kr
  • 2Division of Gastroenterology, Department of athology,College of Medicine, Kwandong University, Goyang, Korea.

Abstract

Tuberculosis is one of the main infectious health problems in Korea, and a combination of antibiotics is required to treat this illness. The combination therapy with rifampicin, isoniazid, ethambutol and pyrazinamide has many adverse reactions and there have been several case reports about pseudomembranous colitis (PMC) after anti- tuberculosis treatment. Rifampicin is regarded as a main cause of anti-tuberculosis induced PMC because of its bacteriocidal effect, and interruption of the offending drug, such as rifampicin, is usually necessary to treat the PMC. However, in patents with uncompensated tuberculosis, the discontinuance of anti-tuberculosis medication accentuates the disease severity, and continuance of the anti-tuberculosis medication is necessary to overcome the tuberculosis. We report here on a case in which the anti- tuberculosis agents induced PMC in 32 year old female who was diagnosed with active pulmonary tuberculosis. She was treated with maintenance of the anti-tuberculosis medication and also the addition of both oral metronidazole and probiotics.

Keyword

Pseudomembranous colitis (PMC); Anti- tuberculosis agents

MeSH Terms

Anti-Bacterial Agents
Enterocolitis, Pseudomembranous
Ethambutol
Female
Humans
Isoniazid
Korea
Metronidazole
Probiotics
Pyrazinamide
Rifampin
Tuberculosis
Tuberculosis, Pulmonary
Anti-Bacterial Agents
Ethambutol
Isoniazid
Metronidazole
Pyrazinamide
Rifampin
Full Text Links
  • KJGE
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr